|By Business Wire||
|May 12, 2014 05:30 AM EDT||
Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions, taking place at the Palais des Congrès May 20-23, 2014 in Paris. The company will exhibit in booth M35 (Level 2), featuring both the new CE approval for left main use of the Tryton Side Branch Stent, and educational resources from the Bifurcation Institute.
Two abstracts are accepted for lecture during Hot Line sessions:
- On Tuesday May 20th, M. B. Leon presents the “1 year results of the randomized IDE study” during the hotline session on Procedural strategies from 12:00 to 13:30 in Room Maillot.
- On Thursday May 22nd, Robert-Jan van Geuns addresses the outcomes of the “Dedicated bifurcation stent in left main coronary artery: 6-month angiography and IVUS results of a prospective registry” from 14:40-15:40 in Room 253.
On Thursday, May 22nd, Martin B. Leon M.D. and Maciej Lesiak M.D., will chair the symposium “Tryton IDE Study outcomes: the change in daily practice treating bifurcations”. The symposium will provide detailed insights into both the 1 year clinical follow-up of the Tryton randomized IDE study and the Tryton Side Branch Stent left main experience. Antonio Bartorelli, M.D., Jens F. Lassen, M.D. and Robert-Jan Van Geuns M.D., will present during the symposium and address the impact of the growing clinical evidence in daily practice. The symposium will take place from 4:50PM – 6:20PM in room 241.
“In line with my own clinical experience, subgroup analysis of the Tryton Medical Bifurcation Stent trial shows that in side branches 2.25mm and larger the clinical and angiographic performance is improved compared to the provisional arm”, says William Wijns, M.D., Ph.D., of the Cardiovascular Center, Aalst, Belgium.
About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.
About the Tryton Side Branch Stent System
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
About the Bifurcation Institute
The Bifurcation Institute is a comprehensive education resource established to advance the standard of care for bifurcated coronary artery disease, a common, and often untreated, clinical need. For more information please visit www.bifurcationinstitute.com.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole of Spray Venture Partners to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3x5 Special Opportunity Fund. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.